Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 08 2021
Historique:
received: 08 01 2021
accepted: 06 07 2021
entrez: 12 8 2021
pubmed: 13 8 2021
medline: 24 8 2021
Statut: epublish

Résumé

Complement is an enzymatic humoral pattern-recognition defence system of the body. Non-specific deposition of blood biomolecules on nanomedicines triggers complement activation through the alternative pathway, but complement-triggering mechanisms of nanomaterials with dimensions comparable to or smaller than many globular blood proteins are unknown. Here we study this using a library of <6 nm poly(amido amine) dendrimers bearing different end-terminal functional groups. Dendrimers are not sensed by C1q and mannan-binding lectin, and hence do not trigger complement activation through these pattern-recognition molecules. While, pyrrolidone- and carboxylic acid-terminated dendrimers fully evade complement response, and independent of factor H modulation, binding of amine-terminated dendrimers to a subset of natural IgM glycoforms triggers complement activation through lectin pathway-IgM axis. These findings contribute to mechanistic understanding of complement surveillance of dendrimeric materials, and provide opportunities for dendrimer-driven engineering of complement-safe nanomedicines and medical devices.

Identifiants

pubmed: 34381048
doi: 10.1038/s41467-021-24960-6
pii: 10.1038/s41467-021-24960-6
pmc: PMC8357934
doi:

Substances chimiques

Dendrimers 0
Drug Carriers 0
Immunoglobulin M 0
Mannose-Binding Lectin 0
Poly(amidoamine) 0
Polyamines 0
Complement C1q 80295-33-6
Complement System Proteins 9007-36-7
Mannose-Binding Protein-Associated Serine Proteases EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4858

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI154959
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

J Biol Chem. 2005 Aug 12;280(32):29080-7
pubmed: 15955802
Mol Immunol. 2008 Aug;45(14):3797-803
pubmed: 18602161
Mol Immunol. 2010 Aug;47(13):2187-97
pubmed: 20580090
J Control Release. 2017 Jan 28;246:88-97
pubmed: 28040639
J Thromb Haemost. 2011 Mar;9(3):428-40
pubmed: 21155967
Mol Ther. 2021 Mar 3;29(3):898-900
pubmed: 33571463
Nat Nanotechnol. 2011 Feb;6(2):80-1
pubmed: 21293484
Bioconjug Chem. 2015 Jul 15;26(7):1198-211
pubmed: 25654320
Mol Pharm. 2013 Oct 7;10(10):3946-58
pubmed: 24020847
J Control Release. 2014 Sep 28;190:556-62
pubmed: 24746624
Nanomedicine. 2012 Aug;8(6):815-7
pubmed: 22542820
Clin Chem. 1999 Aug;45(8 Pt 1):1190-9
pubmed: 10430784
Mol Pharm. 2015 Jun 1;12(6):1961-9
pubmed: 25950742
Biomaterials. 2017 Jan;112:141-152
pubmed: 27760398
J Cell Mol Med. 2014 Oct;18(10):2020-30
pubmed: 25124749
J Intern Med. 2014 Dec;276(6):579-617
pubmed: 24995512
J Immunol. 2012 Feb 1;188(3):1292-306
pubmed: 22219330
Colloids Surf B Biointerfaces. 2017 Apr 1;152:414-422
pubmed: 28167455
Nat Nanotechnol. 2017 Jan;12(1):48-54
pubmed: 27775724
Front Pharmacol. 2017 May 16;8:261
pubmed: 28559844
Nat Med. 1995 Mar;1(3):237-43
pubmed: 7585040
ACS Nano. 2011 May 24;5(5):3456-68
pubmed: 21438566
ACS Nano. 2018 Jun 26;12(6):5834-5847
pubmed: 29750504
ACS Nano. 2013 Feb 26;7(2):1108-19
pubmed: 23301860
Nat Immunol. 2008 Nov;9(11):1225-35
pubmed: 18820683
Biochem J. 1996 Oct 15;319 ( Pt 2):329-32
pubmed: 8912663
Adv Drug Deliv Rev. 2020;157:83-95
pubmed: 32389761
Nanomedicine. 2014 Nov;10(8):1661-6
pubmed: 24832960
Immunobiology. 2006;211(10):759-66
pubmed: 17113913
Nat Rev Drug Discov. 2019 Dec 9;:
pubmed: 31819218
N Engl J Med. 1952 Dec 11;247(24):921-9
pubmed: 13002648
J Biol Chem. 2002 May 3;277(18):16088-95
pubmed: 11850428
Adv Exp Med Biol. 2008;632:273-92
pubmed: 19025129
Biochim Biophys Acta. 2003 May 30;1648(1-2):115-26
pubmed: 12758154
Semin Immunol. 2017 Dec;34:33-51
pubmed: 28869063
Nat Chem Biol. 2015 Jan;11(1):77-82
pubmed: 25402769
Front Immunol. 2015 Feb 02;6:25
pubmed: 25699044
Immunol Lett. 2004 Sep;95(2):113-28
pubmed: 15388251
ACS Sustain Chem Eng. 2018 Sep 4;6(9):11704-11715
pubmed: 30881771
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):4782-7
pubmed: 11959930
Nat Nanotechnol. 2019 Mar;14(3):260-268
pubmed: 30643271
Annu Rev Immunol. 2014;32:433-59
pubmed: 24499275
Biochim Biophys Acta. 2015 Feb;1850(2):419-25
pubmed: 25463324

Auteurs

Lin-Ping Wu (LP)

Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Department of Pharmacy, University of Copenhagen, Copenhagen Ø, Denmark.
Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People's Republic of China.

Mario Ficker (M)

Department of Chemistry, University of Copenhagen, Frederiksberg C, Denmark.

Jørn B Christensen (JB)

Department of Chemistry, University of Copenhagen, Frederiksberg C, Denmark.

Dmitri Simberg (D)

Translational Bio-Nanosciences Laboratory, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Panagiotis N Trohopoulos (PN)

CosmoPHOS Ltd, Thessaloniki, Greece.

Seyed M Moghimi (SM)

Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Department of Pharmacy, University of Copenhagen, Copenhagen Ø, Denmark. seyed.moghimi@ncl.ac.uk.
School of Pharmacy, King George VI Building, Newcastle University, Newcastle upon Tyne, UK. seyed.moghimi@ncl.ac.uk.
Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. seyed.moghimi@ncl.ac.uk.
Translational and Clinical Research Institute, Faculty of Health and Medical Sciences, Framlington Place, Newcastle University, Newcastle upon Tyne, UK. seyed.moghimi@ncl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH